tbuckley/cabot-search huggingface dataset:
Early and Increased Influenza Activity Among Children — Tennessee, 2022–23 Influenza Season
Authors: Christine M. Thomas, Elizabeth B. White, Noah Kojima, Mary-Margaret A. Fill, Samir Hanna, Timothy F. Jones, Caitlin N. Newhouse, Kelly Orejuela, Emma Roth, Sarah Winders, Daniel R. Chandler, Carlos G. Grijalva, William Schaffner, Jonathan E. Schmitz, Juliana DaSilva, Marie K. Kirby, Alexandra M. Mellis, Melissa A. Rolfes, Kelsey M. Sumner, Brendan Flannery, H. Keipp Talbot, John R. Dunn
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

Influenza seasons typically begin in October and peak between December and February (1); however, the 2022-23 influenza season in Tennessee began in late September and was characterized by high pediatric hospitalization rates during November. This report describes a field investigation conducted in Tennessee during November 2022, following reports of increasing influenza hospitalizations. Data from surveillance networks, patient surveys, and whole genome sequencing of influenza virus specimens were analyzed to assess influenza activity and secondary illness risk. Influenza activity increased earlier than usual among all age groups, and rates of influenza-associated hospitalization among children were high in November, reaching 12.6 per 100,000 in children aged <5 years, comparable to peak levels typically seen in high-severity seasons. Circulating influenza viruses were genetically similar to vaccine components. Among persons who received testing for influenza at outpatient clinics, children were twice as likely to receive a positive influenza test result as were adults. Among household contacts exposed to someone with influenza, children were more than twice as likely to become ill compared with adults. As the influenza season continues, it is important for all persons, especially those at higher risk for severe disease, to protect themselves from influenza. To prevent influenza and severe influenza complications, all persons aged ≥6 months should get vaccinated, avoid contact with ill persons, and take influenza antivirals if recommended and prescribed.
Migrant skin health: perspectives from the Migrant Health Summit, Malta, 2022
Authors: Valeska Padovese, Lucinda C Fuller, Christopher E M Griffiths, Toby Maurer, Esther Freeman, Federica Dassoni, Wendemagegn Enbiale, Amy Forrestel, Alexia Knapp, Sidra Khan, Rod Hay, Carmen Logie, Su M Lwin, Ismael Maatouk, Aldo Morrone, Bayanne Olabi, Isotta Rossoni, Aisha Sethi, Apostolos Veizis
Journal: British Journal of Dermatology (2023)

Skin diseases are listed among the most common health issues in refugee camps, yet the lack of skilled professionals, scarce diagnostics and formularies lead to inadequate provision of care for these people. This perspective highlights the possible role of dermatologists in escalating dermatological care to migrants and displaced persons in humanitarian crises.
Alcohol Use, Screening, and Brief Intervention Among Pregnant Persons — 24 U.S. Jurisdictions, 2017 and 2019
Authors: Jackie Luong, Amy Board, Lucas Gosdin, Janae Dunkley, JoAnn M. Thierry, Marc Pitasi, Shin Y. Kim
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

Alcohol use during pregnancy is a major preventable cause of adverse alcohol-related outcomes, including birth defects and developmental disabilities.* Alcohol screening and brief intervention (ASBI) is an evidence-based primary care tool that has been shown to prevent or reduce alcohol consumption during pregnancy; interventions have resulted in an increase in the proportion of pregnant women reporting abstinence (odds ratio = 2.26; 95% CI = 1.43-3.56) (1). Previous national estimates have not characterized ASBI in populations of pregnant persons. Using 2017 and 2019 Behavioral Risk Factor Surveillance System (BRFSS) data, CDC examined prevalence of ASBI and characteristics of pregnant persons and nonpregnant women aged 18-49 years (reproductive-aged women) residing in jurisdictions that participated in the BRFSS ASBI module. During their most recent health care visit within the past 2 years, approximately 80% of pregnant persons reported being asked about their alcohol use; however, only 16% of pregnant persons who self-reported current drinking at the time of the survey (at least one alcoholic beverage in the past 30 days) were advised by a health care provider to quit drinking or reduce their alcohol use. Further, the prevalence of screening among pregnant persons who did not graduate from high school was lower than that among those who did graduate from high school or had at least some college education. This gap between screening and brief intervention, along with disparities in screening based on educational level, indicate missed opportunities to reduce alcohol use during pregnancy. Strategies to enhance ASBI during pregnancy include integrating screenings into electronic health records, increasing reimbursement for ASBI services, developing additional tools, including electronic ASBI, that can be implemented in a variety of settings (2,3).
<i>Erratum:</i> Vol. 71, No. 45
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

on page 1450, the last sentence of the second full paragraph should have read, "Date of vaccination and date of symptom onset was available for 1,563 (6%) patients, 610 (39%) of whom were vaccinated after symptom onset and 953 (61%) before symptoms began."
Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank
Authors: Eric Yuk Fai Wan, Sukriti Mathur, Ran Zhang, Vincent Ka Chun Yan, Francisco Tsz Tsun Lai, Celine Sze Ling Chui, Xue Li, Carlos King Ho Wong, Esther Wai Yin Chan, Kai Hang Yiu, Ian Chi Kei Wong
Journal: Cardiovascular Research (2023)

This study aims to evaluate the short- and long-term associations between COVID-19 and development of cardiovascular disease (CVD) outcomes and mortality in the general population.A prospective cohort of patients with COVID-19 infection between 16 March 2020 and 30 November 2020 was identified from UK Biobank, and followed for up to 18 months, until 31 August 2021. Based on age (within 5 years) and sex, each case was randomly matched with up to 10 participants without COVID-19 infection from two cohorts-a contemporary cohort between 16 March 2020 and 30 November 2020 and a historical cohort between 16 March 2018 and 30 November 2018. The characteristics between groups were further adjusted with propensity score-based marginal mean weighting through stratification. To determine the association of COVID-19 with CVD and mortality within 21 days of diagnosis (acute phase) and after this period (post-acute phase), Cox regression was employed. In the acute phase, patients with COVID-19 (n = 7584) were associated with a significantly higher short-term risk of CVD {hazard ratio (HR): 4.3 [95% confidence interval (CI): 2.6- 6.9]; HR: 5.0 (95% CI: 3.0-8.1)} and all-cause mortality [HR: 81.1 (95% CI: 58.5-112.4); HR: 67.5 (95% CI: 49.9-91.1)] than the contemporary (n = 75 790) and historical controls (n = 75 774), respectively. Regarding the post-acute phase, patients with COVID-19 (n = 7139) persisted with a significantly higher risk of CVD in the long-term [HR: 1.4 (95% CI: 1.2-1.8); HR: 1.3 (95% CI: 1.1- 1.6)] and all-cause mortality [HR: 5.0 (95% CI: 4.3-5.8); HR: 4.5 (95% CI: 3.9-5.2) compared to the contemporary (n = 71 296) and historical controls (n = 71 314), respectively.COVID-19 infection, including long-COVID, is associated with increased short- and long-term risks of CVD and mortality. Ongoing monitoring of signs and symptoms of developing these cardiovascular complications post diagnosis and up till at least a year post recovery may benefit infected patients, especially those with severe disease.
JAMA Oncology
Journal: JAMA Oncology (2023)

JAMA Oncology is committed to publishing infl uential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.Mission Statement JAMA Oncology is the defi nitive journal for scientists, clinicians, and trainees in the fi eld of oncology worldwide.Our original, innovative, and timely scientifi c and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers.JAMA Oncology aims to eff ectively convey the fi ndings of important clinical research, major scientifi c breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community.Our goal is that successful communication of new knowledge will ultimately translate to clinical benefi t for people living with and surviving cancer.
A Novel Tri‐Functional Liposome Re‐Educates “Cold Tumor” and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PD‐L1 Blockade
Authors: Fei Zhou, Xiaojiaoyang Li, Xiaoyong Xue, Shuo Li, Guifang Fan, Yajie Cai, Zihao Chang, Jiaorong Qu, Runping Liu
Journal: Advanced Healthcare Materials (2023)

Abstract Immunotherapy has been regarded as a breakthrough in cancer treatment and achieved great success. However, the poor response rate is still a formidable challenge of current immunotherapies, especially in solid tumors without sufficient infiltration of immune cells, also known as “cold tumor.” SAR405 is a highly specific VPS34 inhibitor and has been suggested as a potential approach converting “cold tumor” into “hot tumor” by inhibiting autophagy. In this study, a tri‐functional doxorubicin (DOX) plus SAR405 liposome system is established and further modified with a novel anti‐PD‐L1 peptide JY4 for targeted delivery (DOX‐SAR‐JY4 LIPO ). The data here demonstrate that in a lung cancer xenograft mouse model, by facilitating the tumoral enrichment of both SAR405 and DOX, DOX‐SAR‐JY4 LIPO effectively increases the infiltration of cytotoxic lymphocytes in the tumor by synergizing DOX‐induced immunogenic cell death (ICD) and SAR405‐mediated upregulation of chemokines including CCL5 and CXCL10. As results, DOX‐SAR‐JY4 LIPO significantly inhibits tumor growth, metastasis, and resurrection by re‐educating immunosuppressive tumor microenvironment. In conclusion, this study not only proves the concept of inhibiting autophagy for better immune infiltration in the tumor but also presents a novel tri‐functional liposomal system that overcomes the deficiencies of current therapies and holds great promise in cancer immunotherapy.
Hierarchical Topography with Tunable Micro‐ and Nanoarchitectonics for Highly Enhanced Cardiomyocyte Maturation via Multi‐Scale Mechanotransduction
Authors: Hyunah Ahn, Younghak Cho, Geun‐Tae Yun, Kwang Bo Jung, Wonji Jeong, Yesol Kim, Mi‐Young Son, Eunjung Lee, Sung Gap Im, Hee‐Tae Jung
Journal: Advanced Healthcare Materials (2023)

Enhancing cardiomyocyte (CM) maturation by topographical cues is a critical issue in cardiac tissue engineering. Thus far, single-scale topographies with a broad range of feature shapes and dimensions have been utilized including grooves, pillars, and fibers. This study reports for the first time a hierarchical structure composed of nano-pillars (nPs) on micro-wrinkles (µWs) for effective maturation of CMs. Through capillary force lithography followed by a wrinkling process, vast size ranges of topographies are fabricated, and the responses of CMs are systematically investigated. Maturation of CMs on the hierarchical structures is highly enhanced compared to a single-scale topography: cardiac differentiation of H9C2s (rat cardiomyocytes) on the hierarchical topography is ≈ 2.8 and ≈ 1.9 times higher than those consisting of single-scale µWs and nPs. Both nPs and µWs have important roles in cardiac maturation, and the aspect ratio (height/diameter) of the nPs and the wavelength of the µWs are important in CM maturation. This enhancement is caused by strong focal adhesion and nucleus mediated mechanotransduction of CMs from the confinement effects of the different wavelengths of µWs and the cellular membrane protrusion on the nPs. This study demonstrates how a large family of hierarchical structures is used for cardiac maturation.
Evaluation of bacterial attachment on mineralized collagen scaffolds and addition of manuka honey to increase mesenchymal stem cell osteogenesis
Authors: Marley J. Dewey, Alan J. Collins, Aleczandria Tiffany, Victoria R. Barnhouse, Crislyn Lu, Vasiliki Kolliopoulos, Isha Mutreja, Noreen J. Hickok, Brendan A.C. Harley
Journal: Biomaterials (2023)
Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial
Authors: Francisco Moniche, Juan Antonio Cabezas-Rodriguez, Roberto Valverde, Irene Escudero-Martinez, Lucia Lebrato-Hernandez, Blanca Pardo-Galiana, Leire Ainz, Manuel Medina-Rodriguez, Javier de la Torre, Virginia Escamilla-Gomez, Joaquin Ortega-Quintanilla, Elena Zapata-Arriaza, Asier de Albóniga-Chindurza, Fernando Mancha, Miguel-Angel Gamero, Soledad Perez, Raul Espinosa-Rosso, Lucia Forero-Diaz, Miguel Moya, Pilar Piñero, Cristina Calderón-Cabrera, Sonia Nogueras, Rosario Jimenez, Vanesa Martin, Fernando Delgado, Juan-José Ochoa-Sepúlveda, Blanca Quijano, Rosario Mata, Monica Santos-González, Gloria Carmona-Sanchez, Concha Herrera, Alejandro Gonzalez, Joan Montaner
Journal: The Lancet Neurology (2023)
How prepared is the world? Identifying weaknesses in existing assessment frameworks for global health security through a One Health approach
Authors: Tieble Traore, Sarah Shanks, Najmul Haider, Kanza Ahmed, Vageesh Jain, Simon R Rüegg, Ahmed Razavi, Richard Kock, Ngozi Erondu, Afifah Rahman-Shepherd, Alexei Yavlinsky, Leonard Mboera, Danny Asogun, Timothy D McHugh, Linzy Elton, Oyeronke Oyebanji, Oyeladun Okunromade, Rashid Ansumana, Mamoudou Harouna Djingarey, Yahaya Ali Ahmed, Amadou Bailo Diallo, Thierno Balde, Ambrose Talisuna, Francine Ntoumi, Alimuddin Zumla, David Heymann, Ibrahima Socé Fall, Osman Dar
Journal: The Lancet (2023)
Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR)
Authors: David A. Baidal, Cassandra M. Ballou, Michael R. Rickels, Thierry Berney, Francois Pattou, Elizabeth H. Payne, Franca B. Barton, Rodolfo Alejandro
Journal: Diabetes Care (2023)

OBJECTIVE To determine C-peptide measures and levels associated with positive glycemic control outcomes following islet transplant (ITx) in type 1 diabetes. RESEARCH DESIGN AND METHODS We evaluated Collaborative Islet Transplant Registry (CITR) islet-alone recipients with pretransplant C-peptide &amp;lt;0.1 nmol/L and mean follow-up of 4.6 ± 1.1 years (n = 677). Receiver operating characteristic area under the curve (ROC-AUC) was used to evaluate the predictive value of fasting and stimulated glucose and C-peptide measures for seven primary outcomes: 1) absence of severe hypoglycemic events (ASHEs); 2) HbA1c &amp;lt;7.0%; 3) HbA1c &amp;lt;7.0% and ASHEs; 4) HbA1c ≤6.5%; 5) HbA1c ≤6.5% and ASHEs; 6) insulin independence; and 7) ASHEs, HbA1c ≤6.5%, and insulin independence (the optimal outcome). Measures with the highest ROC-AUC were selected for determination of optimal cut points. RESULTS Fasting C-peptide was highly predictive for ASHE (ROC-AUC 0.906; optimal cut point 0.070 nmol/L) and the optimal outcome (ROC-AUC 0.845; optimal cut point 0.33 nmol/L). Mixed-meal tolerance test (MMTT)–stimulated C-peptide-to-glucose ratio (CPGR) outperformed both fasting and stimulated C-peptide for all outcomes except ASHE. The optimal cut point for the optimal outcome was 0.12 nmol/mmol for MMTT-stimulated CPGR and 0.97 nmol/L for MMTT-stimulated C-peptide. CONCLUSIONS Fasting C-peptide reliably predicts ITx primary outcomes. MMTT-stimulated CPGR provides marginally better prediction for composite ITx outcomes, including insulin independence. In the absence of an MMTT, a fasting C-peptide ≥0.33 nmol/L is a reassuring measure of optimal islet graft function. C-peptide targets represent excellent and easily determinable means to predict glycemic control outcomes after ITx and should be considered as potential goals of β-cell replacement.
Breakthrough treatments for Ebola virus disease, but no access—what went wrong, and how can we do better?
Authors: Els Torreele, Yap Boum, Ismael Adjaho, Franck Guy Biaou Alé, Sal Ha Issoufou, Geza Harczi, Chibuzo Okonta, Piero Olliaro
Journal: The Lancet Infectious Diseases (2023)
Advancing One human–animal–environment Health for global health security: what does the evidence say?
Authors: Jakob Zinsstag, Andrea Kaiser-Grolimund, Kathrin Heitz-Tokpa, Rajesh Sreedharan, Juan Lubroth, François Caya, Matthew Stone, Hannah Brown, Bassirou Bonfoh, Emily Dobell, Dilys Morgan, Nusrat Homaira, Richard Kock, Jan Hattendorf, Lisa Crump, Stephanie Mauti, Victor del Rio Vilas, Sohel Saikat, Alimuddin Zumla, David Heymann, Osman Dar, Stéphane de la Rocque
Journal: The Lancet (2023)
Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial
Authors: Wolfgang Köhler, Marc Engelen, Florian Eichler, Robin Lachmann, Ali Fatemi, Jacinda Sampson, Ettore Salsano, Josep Gamez, Maria Judit Molnar, Sílvia Pascual, Maria Rovira, Anna Vilà, Guillem Pina, Itziar Martín-Ugarte, Adriana Mantilla, Pilar Pizcueta, Laura Rodríguez-Pascau, Estefania Traver, Anna Vilalta, María Pascual, Marc Martinell, Uwe Meya, Fanny Mochel, Eavan Mc Govern, Elise Yazbeck, Magali Barbier, Marie-Pierre Luton, Françoise Pousset, Jean-Yves Hogrel, Isaac Adanyeguh, Florian Then Bergh, Caroline Bergner, Astrid Unterlauft, Hannes Roicke, Karl-Titus Hoffmann, Cordula Scherlach, Andrea Kalb, Bianca Meilick, Mandy Reuschel, Silvia Fenu, Elena Mauro, Elaine Murphy, Gauri Krishna, Tiggy Beyene, Alba Sierra, Sara Quiñoa, Anna Belen Canovas, Zoltan Grosz, Báthori Györgyi, S.I. van de Stadt, I.C. Huffnagel, W.J.C. van Ballegoij, M.M.C. Voermans, Reza Seyedsadjadi, Camille Corre, Neha Godbole, Natalie Rose Grant, Claudia Maria Brito Pires, Melissa Trovato, Nancy Yeh, Jordan Goodman, Jennifer Keller, Chris Joseph, Keith Van Haren, Sarada Sakamuri, Tina Duong, Lila Perrone, Stephanie Tran, Sally Dunaway Young, Syed Hashmi
Journal: The Lancet Neurology (2023)
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
Authors: Kohei Nakachi, Masafumi Ikeda, Masaru Konishi, Shogo Nomura, Hiroshi Katayama, Tomoko Kataoka, Akiko Todaka, Hiroaki Yanagimoto, Soichiro Morinaga, Shogo Kobayashi, Kazuaki Shimada, Yu Takahashi, Toshio Nakagohri, Kunihito Gotoh, Ken Kamata, Yasuhiro Shimizu, Makoto Ueno, Hiroshi Ishii, Takuji Okusaka, Junji Furuse, Keiya Okamura, Yasuyuki Kawamoto, Akio Katanuma, Michiaki Unno, Hirofumi Shirakawa, Hironori Yamaguchi, Amane Takahashi, Masafumi Ikeda, Hiroo Yanagibashi, Naoya Kato, Takuji Okusaka, Yoshihiro Sakamoto, Yasushi Kojima, Ryota Higuchi, Naoki Sasahira, Keiji Sano, Toshio Nakagohri, Yu Sunakawa, Soichiro Morinaga, Yusuke Kumamoto, Kazuya Sugimori, Tatsuya Nomura, Kazuto Shibuya, Isamu Makino, Kentaro Yamazaki, Nobumasa Mizuno, Ken Kamata, Hiroshi Wada, Kunihito Gotoh, Mitsugu Sekimoto, Tetsuo Ajiki, Ikuo Nakamura, Ikuya Miki, Hiroaki Nagano, Koji Ohta, Takehiro Okabayashi, Masayuki Furukawa, Nao Fujimori
Journal: The Lancet (2023)
Global and regional governance of One Health and implications for global health security
Authors: Azza Elnaiem, Olaa Mohamed-Ahmed, Alimuddin Zumla, Jeffrey Mecaskey, Nora Charron, Mahamat Fayiz Abakar, Tajudeen Raji, Ammad Bahalim, Logan Manikam, Omar Risk, Ebere Okereke, Neil Squires, John Nkengasong, Simon R Rüegg, Muzamil M Abdel Hamid, Abdinasir Y Osman, Nathan Kapata, Robyn Alders, David L Heymann, Richard Kock, Osman Dar
Journal: The Lancet (2023)
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials
Authors: Brandon Essink, Laurence Chu, William Seger, Elizabeth Barranco, Nancy Le Cam, Hamilton Bennett, Veronica Faughnan, Rolando Pajon, Yamuna D Paila, Brooke Bollman, Steven Wang, Jacqueline Dooley, Shiva Kalidindi, Brett Leav
Journal: The Lancet Infectious Diseases (2023)
Exploring the potential to enhance drug distribution in the brain subregion via intranasal delivery of nanoemulsion in combination with borneol as a guider
Authors: Xin Shen, Zhixiang Cui, Yidan Wei, Yingnan Huo, Duo Yu, Xin Zhang, Shirui Mao
Journal: Asian Journal of Pharmaceutical Sciences (2023)

The number of people with Alzheimer's disease (AD) is increasing annually, with the nidus mainly concentrated in the cortex and hippocampus. Despite of numerous efforts, effective treatment of AD is still facing great challenges due to the blood brain barrier (BBB) and limited drug distribution in the AD nidus sites. Thus, in this study, using vinpocetine (VIN) as a model drug, the objective is to explore the feasibility of tackling the above bottleneck via intranasal drug delivery in combination with a brain guider, borneol (BOR), using nanoemulsion (NE) as the carrier. First of all, the NE were prepared and characterized. In vivo behavior of the NE after intranasal administration was investigated. Influence of BOR dose, BOR administration route on drug brain targeting behavior was evaluated, and the influence of BOR addition on drug brain subregion distribution was probed. It was demonstrated that all the NE had comparable size and similar retention behavior after intranasal delivery. Compared to intravenous injection, improved brain targeting effect was observed by intranasal route, and drug targeting index (DTI) of the VIN-NE group was 154.1%, with the nose-to-brain direct transport percentage (DTP) 35.1%. Especially, remarkably enhanced brain distribution was achieved after BOR addition in the NE, with the extent depending on BOR dose. VIN brain concentration was the highest in the VIN-1-BOR-NE group at BOR dose of 1 mg/kg, with the DTI reaching 596.1% and the DTP increased to 83.1%. BOR could exert better nose to brain delivery when administrated together with the drug via intranasal route. Notably, BOR can remarkably enhance drug distribution in both hippocampus and cortex, the nidus areas of AD. In conclusion, in combination with intranasal delivery and the intrinsic brain guiding effect of BOR, drug distribution not only in the brain but also in the cortex and hippocampus can be enhanced significantly, providing the perquisite for improved therapeutic efficacy of AD.
Pediatric Allergic Contact Dermatitis Registry patch testing results from 2016 to 2022: A retrospective study of age-related differences
Authors: Katherine Young, Reid W. Collis, David Sheinbein, Chelsea Shope, Tara Suresh, Idy Tam, Alan Snyder, Colleen Cotton, Raegan Hunt, Alina Goldenberg, Ari Goldminz, Aida Lugo-Somolinos, Eric Grisham, Kari L. Martin, Mandeep Sandhu, Dawn Z. Eichenfield, Jessica Sprague, Elana P. Kleinman, Katie Sum, Jennifer K. Chen, Joyce Teng, Marcella R. Aquino, John Plante, Katlein Franca, Alejandra Onate, Patricia Udrizar, Walter Liszewski, JiaDe Yu
Journal: Journal of the American Academy of Dermatology (2023)